Recent concerns for pharmaceutical companies have centered on President Trump’s plans to reduce drug prices and impose tariffs on imports, causing investor hesitation. However, Pfizer became the first drugmaker to secure a pricing agreement with Trump, gaining a three-year exemption from import tariffs, which led to a 14% surge in its stock over two trading sessions.
